25 Trials Using Mass Cytometry Initiated in 2020
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (Globe NEWSWIRE) — Fluidigm Company (NASDAQ:FLDM), an progressive biotechnology instruments supplier with a vision to make improvements to life as a result of detailed health perception, currently announced that its mass cytometry technologies, such as CyTOF® , Imaging Mass Cytometry (IMC), and Maxpar® Direct™, have been utilized in 113 Nationwide Medical Trials shown in the clinicaltrials.gov databases. This involves 94 ongoing and 19 done clinical trials. 20-five trials were being initiated in 2020, 3 of which make use of Imaging Mass Cytometry.
Fluidigm® mass cytometry systems have been deployed in numerous medical trials connected to the COVID-19 pandemic, which includes evaluation of immune response at unique stages of the illness method and evaluation of response to remedy at the cellular and molecular levels. These technologies are also becoming used in clinical trials for varied indications and interventions in immuno-oncology, oncology, autoimmune conditions, vaccines, infections, surgical treatment, blood and immune issues, immunology, and allergy.
“The large and rising number of clinical trials using our mass cytometry technologies is proof of our development in implementing our vision to boost lifetime by comprehensive health and fitness insight,” stated Chris Linthwaite, President and CEO of Fluidigm. “We are gratified that our systems are enabling slicing-edge discoveries that have the prospective to rework scientific demo style and design and implementation, and we feel that eventually they will assist to advance scientific follow to realize enhanced overall health results.
“The fast deployment of our systems to assist scientific analysis addressing the current world well being disaster demonstrates the flexibility with which these systems can be adapted to fulfill unique and urgent investigation objectives, together with pandemic reaction.”
Illustrations of the numerous strategies in which Fluidigm mass cytometry systems are remaining incorporated into scientific trials as of September 30, 2020:
“Immunophenotyping Evaluation in a COVID-19 Cohort (IMPACC)” (NCT04378777), “a potential observational cohort surveillance study of up to 2,000 grownup contributors hospitalized with identified or presumptive COVID-19,” explores how selected immunological actions correspond to, or may possibly even forecast, the scientific severity of condition. 10 foremost U.S. professional medical establishments are engaged in the review, which is sponsored by the Nationwide Institutes of Wellbeing and makes use of CyTOF and the Maxpar® Direct™ Immune Profiling Assay™.
“Collection of Immunology Specimens From Individuals With Cancer or Blood Diseases, and Healthful Volunteers” (NCT03207854), a retrospective medical demo created to “identify improvements in immune method parameters in patients obtaining immunotherapies and compare” them to adjustments in “patients getting common chemotherapy, specific-agent treatment, and nutritious standard volunteers.” This demo works by using CyTOF.
“Olaparib in Managing People with Advanced Glioma, Cholangiocarcinoma, or Good Tumors with IDH1 or IDH2 Mutations” (NCT03212274), a period II trial built to evaluate “how properly olaparib will work in treating people with glioma, cholangiocarcinoma, or sound tumors with IDH1 or IDH2 mutations that have distribute to other destinations in the system and generally are not able to be treated or managed with therapy.” An exploratory aim of this research is to decide irrespective of whether co-happening genetic alterations are associated with ranges of 2-hydroxyglutarate (a marker of cancer development), cure response, and resistance to therapy. This demo employs CyTOF and IMC.
“Study of a New MVA Vaccine for Hepatitis C Virus” (NCT01296451), a review developed to assess the security and efficacy of a new hepatitis C virus vaccine that will also evaluate cellular immune responses subsequent vaccine administration. This demo makes use of CyTOF to perform deep profiling of mobile phenotype and useful condition, all in a single tube.
“In-depth Immunological Investigation of COVID-19 (COntAGIouS)” (NCT04327570), an observational clinical trial made to deliver an “in-depth characterization of the dynamic host immune response to coronavirus SARS-CoV-2” using a transdisciplinary technique “to discover host things resulting in hyper-susceptibility to SARS-CoV-2 an infection, which is urgently necessary for directed healthcare interventions.” This demo works by using CyTOF, the Maxpar Immediate Immune Profiling Assay, and the Maxpar Pathsetter™ facts examination option.
Commenting on the COntAGIouS trial, Professor Frederik De Smet, PhD, of the University of Leuven, the lead investigator for the trial, explained, “At the start out of the pandemic the clinicians in our hospital who have been dealing with COVID-19 people asked us to work collaboratively with them to comprehend the immunological aberrations in hospitalized sufferers. To handle this urgent will need for understanding, my lab mixed the Maxpar Immediate Immune Profiling Assay with Maxpar Pathsetter, enabling immediate info assessment devoid of the rapid want for bioinformaticians.
“This is significant, simply because when we’re assessing up to 40 parameters at a time for each and every cell—which is simple using CyTOF—analyzing even a couple hundred thousand cells generates enormous amounts of knowledge. With Maxpar Pathsetter we were being able to set up a information analysis structure that swiftly yielded outcomes that assisted notify our knowledge of the immune response to the virus and offered insights into how to perhaps enhance administration of infected patients. In addition, we carried out intensive bioinformatics analyses to combine all 40 markers to a maximal extent and deep-phenotype each blood sample.”
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and medical exploration, such as cancer, immunology, and immunotherapy. Working with proprietary CyTOF and microfluidics systems, we establish, manufacture, and marketplace multi-omic methods to drive significant insights in overall health and ailment, recognize biomarkers to inform decisions, and speed up the enhancement of much more successful therapies. Our buyers are foremost academic, authorities, pharmaceutical, biotechnology, plant and animal investigate, and scientific laboratories globally. Collectively with them, we strive to enhance the top quality of life for all. For extra info, visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Direct, Imaging Mass Cytometry, IMC, Immune Profiling Assay, Maxpar, and Pathsetter are logos and/or registered logos of Fluidigm Corporation in the United States and/or other international locations. All other logos are the sole home of their respective house owners. Fluidigm goods are delivered for Analysis Use Only. Not for use in diagnostic strategies.
Forward-On the lookout Statements for Fluidigm
This push launch has ahead-searching statements in just the this means of the Private Securities Litigation Reform Act of 1995, together with, between other people, statements with regards to the effect of Fluidigm mass cytometry systems on clinical trials and wellbeing care. Forward-hunting statements are subject matter to quite a few pitfalls and uncertainties that could bring about genuine success to differ materially from at present predicted final results, such as but not constrained to pitfalls relating to issues inherent in producing, producing, launching, marketing and advertising, and offering new products pitfalls relating to organization exploration and advancement and distribution plans and abilities reductions in analysis and improvement spending or variations in funds priorities by prospects opportunity product overall performance and excellent challenges intellectual assets dangers and competitiveness. Data on these and supplemental threats and uncertainties and other information affecting Fluidigm business and working success is contained in Fluidigm’s Annual Report on Kind 10-K for the 12 months ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. These ahead-looking statements communicate only as of the date hereof. Fluidigm disclaims any obligation to update these forward-wanting statements apart from as might be essential by law.
We use our site (fluidigm.com), investor web-site (investors.fluidigm.com), company Twitter account (@fluidigm), Facebook webpage (facebook.com/Fluidigm), and LinkedIn website page (linkedin.com/company/fluidigm-company) as channels of distribution of details about our products and solutions, our planned economic and other announcements, our attendance at future investor and business conferences, and other matters. These kinds of information and facts may well be considered content info, and we might use these channels to comply with our disclosure obligations less than Regulation FD. As a result, buyers need to watch our site and our social media accounts in addition to pursuing our press releases, SEC filings, community meeting calls, and webcasts.
Senior Director, Corporate Communications
650 243 6621
Vice President, Trader Relations
650 416 7423